Type 2 diabetes is characterized by diminished or inappropriate secretion o
f insulin, which could be a defect of either islet cell function or beta -c
ell mass. Quantitation of islet cell populations in postmortem pancreas dem
onstrates little change of beta -cell mass in type 2 diabetes. Reduction of
islet cell mass (up to 30%) is associated largely with islet amyloid depos
ition, and the degree of amyloidosis is independent of the duration of the
disease. Insulin secretory capacity is dependent on both function and mass
of cells. beta -Cell secretion is heterogeneous; increasing glucose concent
rations result in recruitment of beta -cells into the secretory pool, indic
ating a large reserve of secretory capacity that can be recruited in insuli
n resistant conditions. The Starling curve of islet function describes the
relationship of insulin secretion to increasing levels of insulin resistanc
e and hyperglycemia in type 2 diabetes. Longitudinal studies in Macaca mula
tta monkeys show that insulin resistance is accompanied by increased islet
mass and onset of diabetes is associated with deposition of amyloid and red
uction of beta -cells. Increasing the function of unresponsive beta -cells
rather than the mass of cells may be a more effective therapeutic target fo
r type 2 diabetes.